AI assistant
MEMPHASYS LIMITED. — AGM Information 2016
Oct 27, 2016
65314_rns_2016-10-27_2a704963-3a7b-4f55-8383-efe337f380c0.pdf
AGM Information
Open in viewerOpens in your device viewer
==> picture [221 x 64] intentionally omitted <==
ASX Release
NOTICE OF AGM AND UPDATE RE OPTIONS FOR JANUARY 2016 PLACEMENT HOLDERS
Sydney, Friday 28 October2016
Memphasys Limited (ASX: MEM) wishes to announce that its Annual General Meeting will be held at noon on Friday 25 November 2016 at the company’s offices, 30 Richmond Road Homebush West 2140. Notices of the Meeting have been posted to shareholders.
In the posted Notice of Annual General Meeting material, participants in the January 2016 private placement will also receive an explanatory letter about the possible exercise of the attaching options to the placement. An Application Form for the potential exercise of these options is also included.
The options may be exercised subject to the resolution to issue the options being passed at the Annual General Meeting. Placement holders need to pay particular attention to the time constraint between the AGM and the expiry date of the options.
The exercise price of the options is $0.016 and their expiry date is 30 November 2016.
The Company has applied for a waiver under Listing Rule 10.1 from the ASX on the convertible notes announced on Tuesday 20 September 2016 from Company Directors, Alison Coutts and Andrew Goodall. Convertibility of the notes is subject to shareholder approval under Listing Rule 10.11 and will be put forward for approval at a later meeting of shareholders.
For further information please contact:
Alison Coutts Executive Chairman +61 2 8415 7300 [email protected]
About Memphasys
Memphasys Limited (ASX: MEM) specialises in biological separations for high value commercial applications. The Company’s patented membrane processes in combination with electrophoresis, the application of an electrical potential difference across a fluid, enable the separation of high value substances or contaminants from the fluid in which they are contained.
The main application of the technology is the separation of the most viable sperm cells for artificial reproduction, most particularly for human IVF.
Postal Address Contact Details E [email protected] P.O. Box 2202 P +612 8415 7300 W memphasys.com Homebush West NSW 2140 F +612 8415 7399 ABN 33 120 047 556
Memphasys Holdings Limited 30-32 Richmond Road Homebush West NSW 2140